PT  - JOURNAL ARTICLE
AU  - Younes, Mahmoud
AU  - Hamze, Kassem
AU  - Carter, Daniel P.
AU  - Osman, Karen L.
AU  - Vipond, Richard
AU  - Carroll, Miles
AU  - Pullan, Steven T.
AU  - Nassar, Hassan
AU  - Mohamad, Nada
AU  - Makki, Mohamad
AU  - Ghadar, Maysaa
AU  - Nguewa, Paul
AU  - Sater, Fadi Abdel
TI  - B.1.1.7 became the dominant variant in Lebanon
AID  - 10.1101/2021.03.17.21253782
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.17.21253782
4099  - http://medrxiv.org/content/early/2021/03/17/2021.03.17.21253782.short
4100  - http://medrxiv.org/content/early/2021/03/17/2021.03.17.21253782.full
AB  - Recently, a new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) designated VOC 202012/01 (or B.1.1.7 lineage) has become highly prevalent in several countries, after first being described in the United Kingdom (UK). Its rate of transmission has been estimated to be increased compared to other lineages. In the present study, we show the emergence, dominance and the rapid spread of the B.1.1.7 lineage in Lebanon.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialnoneFunding Statementno external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:INSTITUTIONAL REWIEW BOARD "AL-RASSOUL AL AAZAM HOSPITAL", BEIRUT-LEBANONAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata are availabe upon request